PRESS RELEASES

17 February 2021

URSAPHARM Arzneimittel and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19

Read more

17 September 2020

CEBINA reports positive findings on the potency of azelastine, a widely used anti-histamine, as anti-COVID-19 approach

Read more

30 June 2020

Eveliqure secures further private investment to support development of its combined Shigella and ETEC vaccine candidate

Read more

19 November 2020

Eveliqure announces the publication of key preclinical data for its clinical stage vaccine candidate against Shigellosis and ETEC

Read more

9 September 2020

Eveliqure announces the award of a NIAID contract to finance Phase 2 clinical studies of its combined Shigella and ETEC vaccine candidate

Read more

4 June 2020

CEBINA secures seed funding for its unique extended spectrum Coronavirus vaccine

Read more

24 September 2020

Eveliqure announces the initiation of a Phase 1 clinical study of its combined Shigella and ETEC vaccine candidate

Read more

9 July 2020

CEBINA identifies a common antihistamine nasal spray as a potential anti-COVID-19 approach

Read more

2 June 2020

Eveliqure Biotechnologies announces regulatory approval to initiate first clinical trial of its ShigETEC vaccine candidate

Read more

©2021 by CEBINA — All Rights Reserved — Company details — Privacy Policy